These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21933768)

  • 21. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does change in device detected frequency of non-sustained or diverted episodes serve as a marker for inappropriate shock therapy? Analyses from the INTRINSIC RV and ALTITUDE-REDUCES Trials.
    Sullivan RM; Seth M; Berg K; Stolen KQ; Jones PW; Russo AM; Gilliam FR; Olshansky B
    Europace; 2014 May; 16(5):668-73. PubMed ID: 24489072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inappropriate cardioverter-defibrillator discharge continues to be a major problem in clinical practice.
    Jodko Ł; Kornacewicz-Jach Z; Kaźmierczak J; Rzeuski R; Zielonka J; Kaliszczak R; Safranow K
    Cardiol J; 2009; 16(5):432-9. PubMed ID: 19753522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
    Bardy GH; Yee R; Jung W
    J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is inappropriate therapy a resolved issue with current implantable cardioverter defibrillators?
    Brugada J
    Am J Cardiol; 1999 Mar; 83(5B):40D-44D. PubMed ID: 10089838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.
    Raitt MH; Connor WE; Morris C; Kron J; Halperin B; Chugh SS; McClelland J; Cook J; MacMurdy K; Swenson R; Connor SL; Gerhard G; Kraemer DF; Oseran D; Marchant C; Calhoun D; Shnider R; McAnulty J
    JAMA; 2005 Jun; 293(23):2884-91. PubMed ID: 15956633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
    Wilkoff BL; Hess M; Young J; Abraham WT
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
    Wilkoff BL; Ousdigian KT; Sterns LD; Wang ZJ; Wilson RD; Morgan JM;
    J Am Coll Cardiol; 2006 Jul; 48(2):330-9. PubMed ID: 16843184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter investigation of an implantable cardioverter-defibrillator algorithm to detect oversensing.
    Welte N; Strik M; Eschalier R; Mondoly P; Defaye P; Frontera A; Ritter P; Haïssaguerre M; Ploux S; Koneru J; Ellenbogen KA; Bordachar P
    Heart Rhythm; 2017 Jul; 14(7):1008-1015. PubMed ID: 28323174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients: A MADIT-RIT Sub-Study.
    Kutyifa V; Daubert JP; Schuger C; Goldenberg I; Klein H; Aktas MK; McNitt S; Stockburger M; Merkely B; Zareba W; Moss AJ
    Circ Arrhythm Electrophysiol; 2016 Jan; 9(1):e001965. PubMed ID: 26743237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure to deliver a shock in a dual-chamber implantable cardioverter-defibrillator: a case report.
    Sousa PA; Candeias R; Jesus I
    Rev Port Cardiol; 2015; 34(7-8):495.e1-5. PubMed ID: 26148668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implantable cardioverter defribrillator shocks: a troubleshooting guide.
    Swerdlow CD; Zhang J
    Rev Cardiovasc Med; 2001; 2(2):61-72. PubMed ID: 12439383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of right ventricular size to treatment with cardiac resynchronization therapy and the risk of ventricular tachyarrhythmias in MADIT-CRT.
    Doyle CL; Huang DT; Moss AJ; Solomon SD; Campbell P; McNitt S; Polonsky S; Barsheshet A; Aktas M; Tompkins C; Zareba W; Goldenberg I
    Heart Rhythm; 2013 Oct; 10(10):1471-7. PubMed ID: 23872690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of ENHANCED Implantable Cardioverter Defibrillator Programming to Reduce Therapies and Improve Quality of Life (from the ENHANCED-ICD Study).
    Mastenbroek MH; Pedersen SS; van der Tweel I; Doevendans PA; Meine M
    Am J Cardiol; 2016 Feb; 117(4):596-604. PubMed ID: 26732419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.
    Burke MC; Gold MR; Knight BP; Barr CS; Theuns DAMJ; Boersma LVA; Knops RE; Weiss R; Leon AR; Herre JM; Husby M; Stein KM; Lambiase PD
    J Am Coll Cardiol; 2015 Apr; 65(16):1605-1615. PubMed ID: 25908064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.